Prospective Study on the Use of Botiulin Toxin at A Dose of 25 UI in Head and Face Pathologies Refractory to Oral Treatment: Regarding 283 Cases

Abstract Introduction: The use of Botulinum Toxin is increasingly being extended in different conditions refractory to other treatments. Thus, it is being used in dystonias, trigeminal neuralgia, migraines, headaches and alterations of the temporomandibular joint, Objectives: Primary: To assess the analgesic response in the pathologies under study: Chronic migraine. Trigeminal neuralgia (regardless of the affected branch) and involvement of the temporomandibular joint (Bruxism) after therapeutic failure maintained for more than two years of previous oral or topical pharmacological therapies. Secondary: To verify the effectiveness of the treatment after six months. Methods: 283 patients of both sexes were included, aged between 85 and 43 years. The patients studied were separated by sex. Group An over 80 years. Group B: between 65 and 79 years and Group C under 64 years. 25 IU of botulinum toxin type A were administered for trigeminal neuralgia, severe temporomandibular joint (TMJ) pain, migraines and headaches, refractory for two years or more to medical treatments. Results: In all groups, with doses of 25 IU in a single dose, a significant improvement in pain occurred at 6 months. Conclusions: In all groups the effectiveness was greater in trigeminal neuralgia at the established doses P<0.05 and more in the younger group (C) with more than 7 months of improvement in the condition. In the rest of the pathologies treated the results at the established doses are very similar to the referenced studies, although in our case, with significantly lower doses. Keywords: Temporomandibular pain; Trigeminal neuralgia; Headache; Migraine; Botulinum toxin